Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1 Sarcoma 1 Gynecologic 1 CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 18 Small Cell Lung Carcinoma 3 Radiation Pneumonitis 2 Mesothelioma, Malignant 2 Lung Neoplasms 2 Recurrence 1 Mesothelioma 1 Adenocarcinoma of Lung 1

Interventions

Docetaxel 8 pembrolizumab 7 Pemetrexed 5 Carboplatin 5 Erlotinib Hydrochloride 4 toripalimab 3 rociletinib 3 fludarabine 3 Radiosurgery 3 Paclitaxel 3 Oxaliplatin 3 Nivolumab 3 Gemcitabine 3 Etoposide 3 Cyclophosphamide 3 Cisplatin 3 Bevacizumab 3 lorlatinib 2 atezolizumab 2 Vinorelbine 2 Topotecan 2 Radiotherapy 2 Platinum 2 Itraconazole 2 Irinotecan 2 Interleukin-2 2 Cetuximab 2 Albumin-Bound Paclitaxel 2 vinflunine 1 vandetanib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × nintedanib × Thoracic × Clear all

NCT03361319 2020-11-24

N3

Royal Marsden NHS Foundation Trust

Phase 1/2 Withdrawn

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡